Abstract: Gastric cancer is one of the most common malignant tumors in the digestive system, with high heterogeneity and complex molecular characteristics. The emergence of tumor-associated biomarkers, such as HER2, MSI, TMB, and NTRK fusion, and molecular pathological diagnostics have revolutionized the diagnosis and treatment methods of gastric cancer. Screening potential beneficiaries of targeted therapies and immunotherapies based on pathological characteristics and genetic testing results may be a future direction for developing precise treatments for gastric cancer. Next-generation sequencing (NGS) plays an increasingly important role in diagnosing, selecting treatment strategies, and prognostic monitoring of gastric cancer. However, the NGS of gastric cancer remains poorly understood in China. Hence, China Anti-Cancer Association Commitee of Gastric Cancer formulated the Chinese expert consensus on the NGS of gastric cancer based on evidence-based medicine to improve the understanding of clinicians and patients on the NGS of gastric cancer and to guide and standardize its clinical applications in China.